Mount Sinai Logo

Toru Ouchi

Print ProfilePrint Profile


Key Words: BRCA1, BRCA2, breast cancer, tumor suppressor

Molecular Basis for Breast Cancer Development:
Analysis of Tumor Suppressor Proteins
This laboratory is investigating the breast cancer susceptibility genes, BRCA 1 and BRCA 2. Recently, Dr. Ouchi and colleagues demonstrated that the BRCA 1 tumor suppressor acts in concert with STAT1 to differentially activate transcription of a subset of INF- gamma target genes and mediates growth inhibition by this cytokine. Other laboratory studies examine the function of BRCA 1 as a p53 coactivator and BRCA 2 as a physical and functional participant with p53 and RAD 51 in maintaining genome integrity.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr.Ouchi is not currently required to report Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central